Optimizing Immune Checkpoint Inhibitor Selection in Metastatic Clear-Cell Renal Cell Carcinoma

A review published in Expert Opinion on Pharmacotherapy provides a clinical framework for immune checkpoint inhibitor (ICI) management in metastatic clear-cell renal cell carcinoma (ccRCC), evaluating pivotal phase III studies—including CheckMate 214, KEYNOTE-426, JAVELIN Renal 101, CheckMate 9ER, and CLEAR, alongside post-ICI trials CONTACT-03, TiNivo-2, and LITESPARK-011—and real-world evidence. The authors searched PubMed/MEDLINE, Embase, the Cochrane Library, major oncology congress abstracts, and ClinicalTrials.gov for evidence published between January 2015 and September 2026.

Despite the impact of ICIs in metastatic ccRCC, therapeutic selection, post-progression sequencing, and toxicity handling remain clinically challenging in the absence of validated predictive biomarkers. Emerging candidate biomarkers under evaluation include transcriptomic signatures and kidney injury molecule-1 (KIM-1). The authors emphasize that treatment selection requires tailoring regimens by International Metastatic RCC Database Consortium (IMDC) risk group, the presence of sarcomatoid features, disease kinetics, and individual patient preferences. Furthermore, implementation of extended flat dosing schedules, vigilant immune-related adverse event (irAE) surveillance, and tyrosine kinase inhibitor (TKI) dose adjustments are highlighted as essential components of care. Following ICI progression and in the adjuvant space, HIF-2α inhibition is entering clinical practice as management shifts toward dynamic, biology-driven treatment approaches.